Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Amylou C. Dueck et al.|The Lancet Oncology|2021Cited by 255
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C. Watt, Shom Goel, Paloma Cejas et al.|Nature Cancer|2020Cited by 110
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Michelle K. DeMeo et al.|Journal of Clinical Oncology|2019Cited by 82
Temporal and spatial topography of cell proliferation in cancerGiorgio Gaglia, Sandro Santagata, Sheheryar Kabraji et al.|Nature Cell Biology|2022Cited by 65